Marketable Securities

6 Months Ended

Apr. 01, 2017

Investments, Debt and Equity Securities [Abstract]

Marketable Securities

Marketable Securities

The following reconciles the cost basis to fair market value of the Company's equity securities that are classified as available-for-sale. In connection with the acquisition of Cynosure, the Company assumed $82.9 million of short and long-term marketable securities, which were classified as available-for-sale and primarily comprised of state and municipal bonds and U.S. treasury notes. Prior to the end of the second fiscal quarter, the Company liquidated the majority of these investments with the exception of $5.2 million of municipal bonds and recorded a loss of $0.2 million in other income (expenses), net. Subsequent to April 1, 2017, the remaining $5.2 million of investments were liquidated.

As of April 1, 2017, Hologic's marketable securities consist of the following:

	Cost		Gross Unrealized Gains		Gross Unrealized Losses			Other Than Temporary Impairment			Fair Value
Period Ended:
April 1, 2017	$	5.9	$	—	$	(0.4	)	$	—		$	5.5
September 24, 2016	$	2.4	$	—	$	(0.3	)	$	(1.1	)	$	1.0

In the first quarter of fiscal 2017, one of the Company's cost-method equity investments became a marketable security, and the Company recorded the increase in value of $4.0 million to other comprehensive income. In the second quarter of fiscal 2017, the Company sold this marketable security and recorded a gain of $3.8 million in other income (expense), net.

In the first quarter of fiscal 2016, the Company sold all of its shares in one of its marketable securities and recorded a gain of $25.1 million in other income, net.